All News

computer screen safety

Methotrexate Side Effects

Jack Cush, MD

Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of early RA patients starting methotrexate (MTX) shows that in the first year, adverse events (AE) were common, but not serious.

Read Article
RheumNow Podcast square

An Ounce of Prevention (2.4.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

Read Article
pediatric.kid_.jpg

Pediatric Rheumatology Workforce Shortages

Jack Cush, MD

Two recent analyses from the USA and Canada point to a significant unmet need with regard to pediatric rheumatologists.

Read Article
risk2h.jpg

Risk vs. Benefit Lessons from the ORAL Surveillance Study

Jack Cush, MD

In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.

Read Article
virus,COVID,Vaccine, booster

MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients

CDC/MMWR

For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.

Read Article
weight%20loss.jpg

How Preventable Is Rheumatoid Arthritis?

MedPage Today

Women who made at least four healthy lifestyle choices saw their risk of developing rheumatoid arthritis reduced significantly, an analysis of Nurses' Health Study (NHS) data found.

Read Article
RheumNow Podcast square

Believing is Doing (1.21.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. These reports are about better outcomes in Lupus; fewer Gout flares with T2T and the power of belief. 

Read Article
hands.stiff2_.jpg

Referral Rules for At-Risk Inflammatory Arthritis

Jack Cush, MD

A prospective primary care study of patients at-risk for inflammatory arthritis (IA) showed that progression to IA was most likely in those with high anti-CCP antibody titers levels and involvement of the hands/feet/ IA.

Read Article
Finnish Parkinson’s disease (FINPARK) cohort (22,189) looked at the assoc w/ #RA. RA pts using only chloroquine/hydroxychloroquine was associated with a lower risk of developing PD (adjusted OR 0.74); not with other DMARDs https://t.co/yZhgVT0xLh

Links:

Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Dr. Ernest Choy will be joining us at RheumNow Live, leading a presentation on Precision Medicine in Rheumatoid Arthritis. Join the discussion on March 19-20. Invigorate, Instigate and Debate Rheumatology at #RNL2022 https://t.co/4uXQfRvRgc https://t.co/7KcPXadGcY

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: How Preventable Is Rheumatoid Arthritis? https://t.co/epc6BvYKzq https://t.co/2hKIuE66zT

Links:

Dr. John Cush RheumNow ( View Tweet)
Join Dr. Cush at RheumNow Live this March as he presents and discusses Treatment Choices in Refractory RA. https://t.co/11XNOQOwm0 https://t.co/Ar4QeoRRTz

Links:

Dr. John Cush RheumNow ( View Tweet)
Cognitive Function and Rheumatoid Arthritis: Dr. Akhil Sood Interviews Dr. Elena Myasoedova https://t.co/SkB3b4wfIj https://t.co/sXNXlbDddG

Links:

Dr. John Cush RheumNow ( View Tweet)
We are excited to announce that Dr. Janet Pope will be joining us at RheumNow Live, leading a presentation on Drug Cycling vs Switching in RA. Join the discussion on March 19-20, on site or virtually! https://t.co/RfWz53vem3 https://t.co/9n1UzFrkVb

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Infliximab treatment of RMD/IMIDs by targeting drug levels (therapeutic drug monitoring) was superior to usual care in study with more sustained Dz control without worsening in 458 IMID pts Rx for 52 weeks (TDM 74% vs 70% standard Rx) https://t.co/KsnQxYXHkI

Links:

Dr. John Cush RheumNow ( View Tweet)

GWAS study in RA used to develop polygenic risk score (PRS) for Xray progression (training set = 500 and validated testing set= 740). Risk factors for severe XRAY progr = PRS (P=0.00019), female (P=0.0033), ACPA (P=0.0023), BMI (P=0.031) https://t.co/dwDSnTFUqs

Links:

Dr. John Cush RheumNow ( View Tweet)

Referral Rules for At-Risk Inflammatory Arthritis https://t.co/p1sBNSmWF5 https://t.co/tk29UNPYdi

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Peter Nigrovic asserts the division between pediatric and adult arthritis is senseless and has no firm biologic basis. Instead we should consider pts as sero- positive or negative, Systemci or Spondyloarthropathy. @UTSWRheum https://t.co/zx5oQmUQ6Y
Dr. John Cush RheumNow ( View Tweet)
192 early arthritis & 693 early arthralgia underwent the MTP-squeeze-test (MTPsqT) & MRI. Synovitis & intermetatarsal bursitis (IMB) were assoc w/ MTPsqT. In EA, MTPsqT +, 79% had synovitis or IMB: 12% synovitis, 15% IMB & 52% had both. https://t.co/Ojwb8KkmLu

Links:

Dr. John Cush RheumNow ( View Tweet)

Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/c7oLLCllM8 https://t.co/EGCGFilnVv

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×